Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025)

Universe Pharmaceuticals (UPC) has disclosed Current Deferred Revenue for 1 consecutive years, with $40.7 million as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue changed N/A to $40.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $40.7 million through Sep 2025, changed N/A year-over-year, with the annual reading at $40.7 million for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue hit $40.7 million in Q3 2025 for Universe Pharmaceuticals.
  • In the past five years, Current Deferred Revenue ranged from a high of $40.7 million in Q3 2025 to a low of $40.7 million in Q3 2025.